OOWL Metabolomics
Acquired by Laboratorios Rubió, 2023.
OWL Metabolomics no longer appears in the directory or on the maps; no funding rounds are on record.
Source ↗
OWL Metabolomics (legally One Way Liver, S.L., originally One Way Liver Genomics) is a Basque biotech spin-off of CIC bioGUNE founded in 2002-2004 in Derio (Bizkaia) that applies UHPLC-MS metabolomics to liver disease, commercialising the OWLiver and OWLiver Care non-invasive serum diagnostics for NAFLD/MASLD and NASH/MASH plus contract metabolomics R&D services for pharma and clinical trials. It was acquired by Laboratorios Rubió on 14 June 2023 and rebranded as Rubió Metabolomics, so it is no longer an independent company; its HQ is Parque Tecnológico de Bizkaia, Derio. Historic partnerships include Cerba Research/BARC Lab for deploying metabolomics in clinical trials.
SectorsBiotech, Metabolomics, Diagnostics, Liver disease / NASH-MASH, Life sciences R&D services
Founders
J
José María Mato
Co-founder (scientific founder); Scientific Advisory Board member
Global models
No comparables on record yet.
In the same niche 49 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 6
Open as list →C
CRB Health Tech
www.crbinverbio.com
DDozen Investments
www.thecrowdangel.com
K
Kereon Partners
kereonpartners.com
S
SPRI
www.grupospri.eus
FFundació Clínic per a la Recerca Biomèdica
IInstitute for Research in Biomedicine (IRB Barcelona)
Funding rounds
No announced rounds on record.